EPCAM and colon adenocarcinoma: Conversely, a significant reduction in EpCAM expression was noted in colon adenocarcinoma (COAD), glioblastoma multiforme (GBM), as well as in liver hepatocellular carcinoma (LIHC) and renal cancer (Fig. 2A).